盈康生命科技股份有限公司 盈康生命科技股份有限公司 媒体来访和投资者调研接待工作管理办法 （2025 年 6 月） 第一章 总则 第一条 为贯彻证券市场公开、公平、公正原则，规范盈康生命科技股份有限 公司（以下简称"公司"）对外接待行为，加强公司对外接待及与外界的交流和沟 通，提高公司投资者关系管理水平，根据《中华人民共和国公司法》 《中华人民共 和国证券法》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等法律法规和规范性文件以及公司 章程的规定，结合公司实际，制定本办法。 第二条 本规定所述的投资者调研接待工作，是指公司通过接受投资者、媒体、 证券机构的调研、一对一沟通、一对多沟通、现场参观、分析师会议、路演和业 绩说明会、新闻采访等活动，增进资本市场对公司的了解和认同的工作。 第三条 本规定所称重大信息是指对公司股票及其衍生品种交易价格可能或 已经产生较大影响的信息，包括下列信息： （一）与公司业绩、利润分配等事项有关的信息，如财务业绩、盈利预测、 利润分配和资本公积金转增股本等； （二）与公司收购兼并、资产重组等事项有关的信息； （三）与公司股 ...

Core Viewpoint - Bayzed Health Group is set to officially list on the Hong Kong Stock Exchange on June 23, attracting significant investor attention due to its focus on oncology healthcare, despite ongoing controversies regarding its acquisition expansion and goodwill scale [1] Group 1: Company Overview - Bayzed Health Group is a leading private healthcare enterprise specializing in oncology, having expanded from a regional small-scale tumor specialty hospital to a medical service network covering eight hospitals across five provinces since 2018 [2][4] - The company has demonstrated strong growth, with its outpatient and inpatient visits achieving compound annual growth rates of 23.3% and 22.8% respectively from 2022 to 2024, significantly surpassing industry averages [2][7] Group 2: Financial Performance - The company's revenue is projected to grow from 800 million yuan in 2022 to 1.19 billion yuan in 2024, reflecting a compound annual growth rate of 21.7% [4] - Bayzed's gross profit increased from 79.56 million yuan to 210 million yuan during the same period, with an annual growth rate of 61.8% [4] - By 2024, the company is expected to achieve a net operating profit of 12.496 million yuan, marking a turnaround from previous losses [4] Group 3: Acquisition Strategy - The goodwill resulting from acquisitions stands at 643 million yuan, accounting for approximately 29.17% of total assets, which is lower than the industry average of 34.08% [7][8] - Key acquisitions, such as the Beijing Western Tumor Hospital and Wuzhi Jimin Hospital, have led to significant revenue growth and improved operational efficiency, with the former's revenue increasing from 184 million yuan to 322 million yuan from 2022 to 2024 [7][8] Group 4: Market Position and Competitive Advantage - Bayzed Health Group has established a comprehensive oncology service model covering the entire patient journey from early screening to rehabilitation, distinguishing itself from competitors who focus on single aspects of cancer care [10][12] - The company has implemented a digital patient management platform that enhances patient tracking and follow-up, improving survival rates and patient compliance [12][13] Group 5: Future Outlook - With ongoing macroeconomic recovery and continuous growth in performance, Bayzed Health Group is positioned to achieve higher valuation premiums in the market [4][6] - The company is expected to benefit from ongoing healthcare reforms and improvements in medical quality and safety management, further solidifying its competitive advantage [13][14]

Group 1 - The core viewpoint of the news is the performance and structure of the FuGuo Medical Industry Mixed Initiation A fund, which has seen a decline in its net value and cumulative returns since its establishment [1][3] - As of June 19, 2024, the fund's net value is 0.97 yuan, with a drop of 1.68% on that day and a total decline of 6.51% over the past five trading days [1] - The fund was established in May 2024 with a total size of 0.11 billion yuan and has recorded a cumulative return of -3.13% since inception [1] Group 2 - The holder structure of the FuGuo Medical Industry Mixed Initiation A fund shows that institutional investors hold 0.10 billion shares, accounting for 94.23% of the total shares, while individual investors hold 0.01 billion shares, making up 5.77% [1] - As of March 31, 2025, the top ten holdings of the fund account for a total of 57.43%, with significant positions in companies such as Aier Eye Hospital (8.57%), Aibo Medical (8.19%), and DR Huatai Medical (7.20%) [2]

Core Viewpoint - Obesity has become a significant global health issue, with projections indicating that by 2050, the number of overweight and obese individuals aged 25 and above will reach 3.8 billion globally, with China, India, and the United States being the top three countries affected [4]. Group 1: Policy Initiatives - The National Health Commission (NHC) has issued a notification encouraging the establishment of weight management outpatient services in various hospitals, aiming for basic nationwide coverage by June 2025 [4][5]. - The "Healthy Weight Management Year" initiative was launched in 2024, promoting the establishment of health weight management outpatient services or obesity prevention centers in medical institutions [5][6]. Group 2: Implementation and Response - Following the policy announcement, hospitals across the country have actively set up weight management outpatient services, including major hospitals and community health centers [5][6]. - Notable examples include Peking Union Medical College Hospital and Xiangya Hospital, which have established multidisciplinary teams to provide comprehensive weight management services [5][6]. Group 3: Service Features - Weight management outpatient services are designed to offer personalized management plans, integrating various medical disciplines such as endocrinology, nutrition, and traditional Chinese medicine [6][7]. - Hospitals like Xiamen University First Affiliated Hospital and Shanghai Huashan Hospital are utilizing advanced technologies like genetic testing and body composition analysis to tailor treatment plans for patients [6][7]. Group 4: Future Directions - The NHC has outlined specific requirements for hospitals to enhance weight management services, including the establishment of multidisciplinary teams and the promotion of digital management tools [8][9][10]. - The initiative emphasizes the importance of public awareness and education regarding weight management, aiming to create a supportive environment for individuals seeking to manage their weight [12].

Group 1 - Beijing is exploring a new model for the co-construction and sharing of health and medical data, promoting the development of "Internet + Healthcare" with 101 internet hospitals and an annual growth rate of over 50% in internet diagnosis and treatment [1][3] - The Beijing Health Commission has initiated a one-stop service system for research-oriented wards, launching 30 demonstration projects to enhance clinical trial support systems, effectively alleviating the shortage of clinical trial beds and improving management efficiency [1][2] - The time to initiate clinical trials has been reduced to 24.9 weeks, with a faster reduction to 17.1 weeks, a decrease of 7.7 weeks year-on-year, facilitating the approval of 25 innovative drugs [1] Group 2 - The city is expanding international medical service resources, with 52 medical institutions now having international medical departments and 156 institutions providing full-process foreign language services [2] - The 114 appointment registration platform has launched an English version to serve foreign personnel in Beijing, with 8 international medical pilot hospitals now available on the platform [2] - The integration of medical, insurance, and pharmaceutical applications is being promoted through the "Jingtong - Health Service" module, which offers various convenient services, with significant growth in online query capabilities for medical imaging and test reports [3]

Market Overview - On June 19, A-shares opened lower and continued to decline, with the Shanghai Composite Index falling by 0.79% to 3362 points, the Shenzhen Component Index down by 1.21%, and the ChiNext Index down by 1.36%, with over 4600 stocks declining across the market [1] - Market focus shifted towards the oil, natural gas, and digital reading sectors [1] High-Performing Stocks - In the oil and gas sector, Zhuan Oil Co. and Shandong Molong achieved five consecutive trading limits, while military stock Beifang Changlong saw a 20% increase over three days [3] - Notable stocks with significant gains include: - Shandong Quanlong: +10.00%, five consecutive limits [4] - Zhuan Oil Co.: +9.96%, five consecutive limits [4] - Beifang Changlong: +20.01%, three limits in five days [4] - Innovation Medical: +10.04%, two limits in three days [4] Trading Activity - The top three net purchases on the Dragon and Tiger list were: - Innovation Medical: net purchase of 207 million [5] - Electric Science Cybersecurity: net purchase of 153 million [5] - Anni Co.: net purchase of 135 million [5] - The top three net sales were: - Limin Co.: net sale of 230 million [7] - Xiexin Energy: net sale of 218 million [7] - Changshan Pharmaceutical: net sale of 178 million [7] Sector Highlights - Innovation Medical focuses on brain-machine interfaces and AI medical models, achieving a trading limit with a turnover of 1.745 billion and a turnover rate of 31.78% [10] - Baida Qiancheng, involved in short drama games and major contract signings, also reached a trading limit with a turnover of 1.077 billion [14] - Electric Science Cybersecurity, which focuses on digital currency and satellite navigation, achieved a trading limit with a turnover of 694 million [18] Institutional Activity - Institutions showed significant interest in several stocks, with net purchases in: - Electric Science Cybersecurity: 35 million [22] - Innovation Medical: 26 million [22] - Shandong Molong: 20 million [22] - Conversely, institutions sold off stocks like Limin Co. and Xiexin Energy, with net sales of 64 million and 71 million respectively [19][22] Conclusion - The market experienced a downward trend with specific sectors like oil and gas showing resilience through notable stock performances. Institutional trading patterns indicate selective interest in high-growth potential stocks, particularly in the technology and healthcare sectors.

Group 1 - Chengjian Development received a dividend of 7.1282 million yuan from Beijing Jingcheng Jiaye Property Co., Ltd., in which it holds a 33.47% stake [1] - Shengnuo Bio expects a net profit attributable to shareholders of 77.0275 million to 94.1448 million yuan for the first half of 2025, representing a year-on-year increase of 253.54% to 332.10% [1] - JKN2301 dry mixed suspension has been approved for clinical trials, targeting children with influenza [5][6] Group 2 - Jindawei obtained a patent for a method of purifying natto kinase, with a validity of twenty years [2] - CITIC Guoan plans to increase its stake in China Broadcasting Hunan Company to approximately 5.29% through a capital increase of 278 million yuan [2] - Ji Electric announced the resignation of its general manager, Niu Guojun, due to work changes [3] Group 3 - Xintian Green Energy successfully issued 1.5 billion yuan in green medium-term notes with a term of 3+N years and an interest rate of 2.05% [7] - Hengrun Co. plans to invest 1.2 billion yuan in a project to produce 2,000 sets of wind turbine gearbox components [9] - Pulaide received a government subsidy of 10 million yuan, accounting for 15.87% of its audited net profit for the last fiscal year [10] Group 4 - Boteng Co. passed the EU QP audit, receiving a compliance statement for its CDMO services [12] - Zhou Dasheng added 7 self-operated stores in May, with total investments ranging from 900,000 to 6.5 million yuan [13] - Wantai Bio initiated a Phase III clinical trial for its live attenuated varicella vaccine [15] Group 5 - Shanghai Pharmaceuticals received a drug registration certificate for Pregabalin capsules in Thailand [19] - Sanxing Medical's subsidiary is expected to win contracts worth approximately 143 million yuan from State Grid projects [21] - Jiangsu Huachen plans to issue 460 million yuan in convertible bonds [24] Group 6 - Jian Gong Repair won a soil pollution remediation project worth 32.76 million yuan [25] - Dize Pharmaceutical completed patient enrollment for a global Phase III clinical trial of its drug [26] - Del Co. received acceptance for its application to issue shares for asset acquisition and raise matching funds [27] Group 7 - Beijing Kerui won multiple power grid projects with a total value of approximately 154 million yuan [27] - Xie Chuang Data signed financing lease contracts totaling 498 million yuan with Su Yin Financial Leasing [28] - Meige Intelligent submitted an application for H-share listing on the Hong Kong Stock Exchange [29][31] Group 8 - Aikodi plans to repurchase shares worth 100 million to 200 million yuan for employee stock ownership plans [54] - Kong Kong Industrial intends to sell 80% of Tianyuan Construction to its controlling shareholder [55] - Youyou Green Energy proposed a cash dividend of 12 yuan per 10 shares, totaling 50.4 million yuan [55]

随着医疗需求来越越多元化和个性化，非急救转运以及跨省转 运的使用场景会越来越多，这意味着，非急救转运服务体系亟 待完善。近年来，多地都在探索建立规范化的非急救转运服务 体系。 作者： 言咏 封图：图虫创意 通报中提到"就诊医院无符合跨省转运条件的救护车"，这亦是公众关切之处。患儿家属表示，当时 也觉得费用昂贵，但情况紧急，不容多考虑。这是人之常情。孩子病情危重，做父母的但凡拿得出 钱来都不会退却。可以说，这种"同意"并非基于完全平等的自由议价，带有很强的无奈，也反映出 医疗转运服务体系的短板。公众不禁要问：就诊医院为何没有符合跨省转运条件的救护车？除了民 营救护车，还有其他更平价的选择吗？2.8万元不是一个小数目，不是谁都花得起。如果花不起， 家属要如何抉择呢？ 中国公立系统的救护车很少执行跨省转运业务，是因为制度限制、资源分配和职能划分等多重因 素。我国救护车服务分院前急救和非急救转运两类。院前急救由公立系统负责，多为属地化管理， 主要服务辖区内急救需求，很少用于跨省转运；非急救转运则多由民营机构运营。根据《院前医疗 急救管理办法》，前者不得用于非院前医疗急救服务。这一制度设计旨在平衡急救资源的公益性和 使 ...

（原标题：救护车收费2.8万 江西通报未解公众关切） 言咏 | 文 针对江西一位父亲对救护车转运其重症孩子时800公里收费2.8万元的投诉，6月18日，江西省 卫健委连夜发布了情况通告。通告认定救护车所有方南昌赣医医院存在收费不合理等问题，卫生健康行 政部门已责令其退回不合理收费，并暂停其医疗转运服务。下一步，江西卫健委将联合相关职能部门对 事件进一步调查核查。 根据通报，这位患儿今年4月在江西省儿童医院心脏重症监护室紧急救治，因病情危重，4月8日19时20 分家属提出急需连夜转运治疗。由于就诊医院无符合跨省转运条件的救护车，经家属请求，诊治医生联 系了赣医医院的救护车。救护车司机与家属沟通，约定转运费2.8万元，分两次支付。江西省儿童医院 派出两名医护人员随车护送，并携带使用ECMO（体外膜肺氧合）等相关抢救设备和药品。4月9日5时 许，救护车到达家属指定的上海某医院紧急救治，患儿转危为安。 通报中提到"就诊医院无符合跨省转运条件的救护车"，这亦是公众关切之处。患儿家属表示，当时也觉 得费用昂贵，但情况紧急，不容多考虑。这是人之常情。孩子病情危重，做父母的但凡拿得出钱来都不 会退却。可以说，这种"同意"并非 ...

Core Viewpoint - The "2025 Health China Innovation Practice Case Collection and Display Activity" has been officially launched to promote innovative practices and advanced experiences in health management and patriotic health movements across various regions and units [1] Group 1: Collection Details - The collection is open to the entire society, including government bodies, public hospitals, schools, research institutions, social organizations, and enterprises [2] - The collection period is from now until September 20, 2025 [3] Group 2: Collection Content - Cases related to health weight management, focusing on innovative management measures and typical experiences in implementing weight management systems [3] - Cases related to medical foundation projects, emphasizing innovations in rural health construction, county medical capacity enhancement, and community health services [3] - Cases in health digitalization and technology transfer, including applications of AI in diagnosis, digital hospital construction, and telemedicine services [3] - Cases in traditional Chinese medicine health initiatives, focusing on cultural literacy, service improvements, and non-drug therapies [4] Group 3: Case Requirements - The submitted cases must be based on real examples, avoiding fabrication or exaggeration [5] - Cases should be typical and provide meaningful solutions that can serve as references for other regions [6] - Submissions must include background, specific measures, and results, supported by data or charts [6] - The logic, methods, and technical solutions in the cases must adhere to scientific principles and comply with policies and ethics [6] Group 4: Submission Method - Cases should be submitted via email, with a specific subject format and additional materials allowed [8] - Contact information for inquiries is provided, including names and phone numbers [8] Group 5: Application of Case Results - Selected cases will be showcased on the People's Health platform [9] - Invited units will participate in case research and exchange to promote results [9] - Eligible cases may become partners in the People's Daily data intelligence program for deeper collaboration [9]